14 results about "Available drugs" patented technology

Disclosed in the present invention are an anti-SARS-CoV-2 arylnaphthalene lignan compound, and a preparation method therefor and the use thereof. Results show that ANL-1, ANL-2, and ANL-4 to ANL-7 have no toxicity to Vero E6 cells, and ANL-3 has low toxicity to Vero E6 cells. In a Vero E6 cell model, the in vitro anti-SARS-CoV-2 activities of ANL-7 and ANL-2, in TI value, are respectively 19 times and 16 times that of remdesivir, and are higher than the in-vitro anti-SARS-CoV-2 activity of a market-available drug. ANL-2 has a significant inhibitory effect on RNA-dependent RdRp activity of SARS-CoV-2, and ANL-2 also effectively limits the replication of various pathogenic coronaviruses in Caco2 cells or hamsters. It can be seen that the arylnaphthalene lignan compound has a good anti-coronavirus activity and can be used for treating and preventing SARS-CoV-2 infection or delaying the progress of SARS-CoV-2 infection in a patient.

Computer method 300 for determining vaccinations and / or medication required by an individual. Method 300 is based on obtaining indications of the individual’s: risk 301; medical history 305 and what vaccinations and / or medication are available 307. Determining what vaccinations and / or medication the individual requires 309 is based on the obtained indications 301, 305, 307. Other embodiments include making this determination by obtaining a list of all diseases present in a region and filtering it based on the individual’s travel plans. Alternatively, a list of all available medication and / or vaccines is obtained and filtered based on travel plans. Further embodiments include a method for adding a new disease to a database; methods for obtaining up-to-date information by periodically crawling travel advice websites to identify any change(s). In the event of change(s) an alert is provided for assessment by a clinician to determine whether a change in medication and / or vaccination are required. Alternatively, a machine learning model may be applied to determine the nature of the change(s) and whether a change in medication and / or vaccine is required.

The invention relates to application of a melaleuca virens essential oil monomer in preparation of a medicine for treating cervicitis. According to the present invention, the monomer with the clear drug effect is separated from the melaleuca virens essential oil, such that the significant effect is provided in the treatment of cervicitis, the problem of the indefinite action mechanism of the melaleuca virens essential oil in the treatment of cervicitis is solved, the drug effect is significantly superior to the commercially available cervical cancer treatment drug, and the broad application prospect is provided.

An anti-SARS-CoV-2 arylnaphthalene lignan compound, and a preparation method therefor and the use thereof. Results show that ANL-1, ANL-2, and ANL-4 to ANL-7 have no toxicity to Vero E6 cells, and ANL-3 has low toxicity to Vero E6 cells. In a Vero E6 cell model, the in vitro anti-SARS-CoV-2 activities of ANL-7 and ANL-2, in TI value, are respectively 19 times and 16 times that of remdesivir, and are higher than the in-vitro anti-SARS-CoV-2 activity of a market-available drug. ANL-2 has a significant inhibitory effect on RNA-dependent RdRp activity of SARS-CoV-2, and ANL-2 also effectively limits the replication of various pathogenic coronaviruses in Caco2 cells or hamsters. It can be seen that the arylnaphthalene lignan compound has a good anti-coronavirus activity and can be used for treating and preventing SARS-CoV-2 infection or delaying the progress of SARS-CoV-2 infection in a patient.

The formulation describe the preparation of an analgesic balm which comprises camphor, menthol, thymol, essential oils; e.g., wintergreen oil, eucalyptus oil, turpentine oil & cinnamomun oil; and hard wax in petroleum jelly base. This preparation is excellent in the precutanous absorption of menthol, thymol and provides good result upon use. It is prepared for topical use and effective for stiff joint pain, sciatica, headache and deep seated muscular pain. Its result is much better than othef marketed available drugs for same purpose.

Omeprazole, as a widely used proton pump inhibitor, is mainly used for the treatment of various diseases caused by excessive gastric acid, such as gastric ulcer, duodenal ulcer and reflux esophagitis. The present application relates to a new use of a commercially available drug omeprazole, i.e. it has significant anti-aging activity. The present application found that omeprazole can significantly prolong the life of nematodes through research using model organisms Caenorhabditis elegans. Specifically, when the nematodes are cultured in a medium containing 1.6 mg / mL and 3.2 mg / mL omeprazole, their life is prolonged by 47.80% and 61.51% respectively, which is extremely rare in current drug research.

The invention discloses an application of vitamin B7 in preparation of a medicine for treating allergic rhinitis. According to the application, virtual screening is performed through clinically available medicines, and the vitamin B7 is locked as a candidate medicine possibly acting on METTL3. Furthermore, in-vitro nasal mucosa epithelial cell experiments and in-vivo mouse model researches prove that the vitamin B7 can effectively reduce the TSLP level and improve AR-related inflammatory reactions, and shows a remarkable treatment effect.

To provide a system for enabling a user to obtain the proposal of a proper drug on the market, the risk check of interaction and the analysis of a side effect risk only by inputting his or her own symptom or drug information during taking, and to select and take the drug without anxiety.SOLUTION: An input unit configured to input information on a drug being taken by a user and a symptom of the drug; a receiving unit configured to receive information transmitted from the input unit; A system comprising: a proposal means for proposing an appropriate commercially available drug based on a symptom; an interaction check means for checking an interaction between a drug being taken and a proposed commercially available drug; a side effect risk analysis means for analyzing a side effect risk based on personal information of a user; an information generation means for summarizing the analysis result and providing the analysis result to the user; SELECTED DRAWING: Figure 1

The invention relates to a lansoprazole and sodium bicarbonate combined medicine and a preparation method thereof. The combined medicine is prepared from lansoprazole, sodium bicarbonate, poloxamer 188, microcrystalline cellulose, croscarmellose sodium and sodium stearyl fumarate. The lansoprazole and sodium bicarbonate combined preparation prepared by the invention is stable and reliable, and is more remarkable in effect through scientific test verification; the lansoprazole and sodium bicarbonate combined preparation prepared by the invention can be rapidly absorbed in vivo, has higher Cmax, is suitable for the requirement of rapid effect taking, has higher AUC and high bioavailability, and is verified to have a very good effect through scientific experiments of pharmacokinetics in rabbits. In conclusion, the lansoprazole and sodium bicarbonate combined medicine prepared by the invention is obviously superior to related existing commercially available medicines.

The present disclosure provides stilbene derivatives and their preparation and use. Specifically, the present disclosure provides the use of a compound represented by Formula I-1, its stereoisomer, pharmaceutically acceptable salt, or prodrug as an aromatic hydrocarbon receptor (AHR) modulator. The compound represented by Formula I-1 has significantly improved photostability of its molecular structure compared to the commercially available drug benvitimod, thereby alleviating benvitimod's photoinstability and susceptibility to decomposition under light irradiation. Furthermore, it has significantly improved activity against the AHR protein. Finally, the compound represented by Formula I-1 can be produced by a simple method at gram or kilogram levels, and has better prospects for subsequent formulation development, safety, and clinical application. [Formula 1] JPEG2025533578000047.jpg26169

The invention discloses a pharmaceutical composition and application thereof, and belongs to the field of medicines. The pharmaceutical composition is prepared from active ingredients, and the active ingredients are prepared from telaprevir and tidutinib. The pharmaceutical composition disclosed by the invention has an excellent effect of preventing, improving and / or treating cognitive impairment, and the telaprevir and the sidumatinib are combined for use to show a synergistic effect, so that a more excellent curative effect can be obtained, the dosage of the medicine is reduced, the clinical medication safety is improved, and the pharmaceutical composition has a relatively good clinical application prospect; in addition, the pharmaceutical composition disclosed by the invention is expected to enrich the types of clinically available drugs in the field of cognitive impairment, so that the problems of drug resistance, safe medication and the like can be better solved.

Disclosed are embodiments of dose tracking devices configured for use with commercially available drug packaging or “blister cards.” The disclosed tracking devices track the removal of drug doses from the “blister cards” with which they interact. A particular disclosed embodiment relates to an electronic tracking module comprising multiple voltage sensors electrically coupled to a circuit trace attached to a drug blister card, which may be commercially available or provided by a healthcare provider. The circuit trace comprises multiple circuits that align with a drug blister containing drug doses. When a dose is removed from the blister, the circuit corresponding to the circuit trace is disconnected, indicating that the dose has been removed. Patient medication information can be transmitted to a remote server for monitoring and data storage.

A multiple times available drug concentration measuring apparatus includes a sample input unit configured to allow a liquid drug sample to be introduced therethrough, a dilution unit configured to add a solvent to a portion of the liquid drug sample in order to dilute the liquid drug sample, a concentration measurement unit configured to measure the concentration of the liquid drug sample using a sensor, and a control unit configured to decide a dilution ratio of the liquid drug sample based on data received from the concentration measurement unit, to perform control such that the dilution unit dilutes the liquid drug sample according to the dilution ratio, and to calculate the concentration of the liquid drug sample based on the dilution ratio and the data received from the concentration measurement unit.

The invention belongs to the technical field of biological medicines, and particularly discloses application of a small molecule compound SHIN1 in preparation of a medicine for treating uveal melanoma (UM). Cell experiments prove that the small molecule compound SHIN1 can significantly inhibit the proliferation and clone formation ability of UM cells, and animal experiments prove that the SHIN1 can inhibit UM tumor formation in vivo. On the basis, a new field of application of SHIN1 to UM treatment is developed, a new treatment medicine is provided for UM, the awkward situation that no medicine can be used for UM clinically is solved, the life of a patient is prolonged, and the life quality of the patient is improved.